Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta

09 Jan 2012
News

Faraz Kermani Faraz.kermani@informa.com

Executive Summary

Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Regions
Europe

Germany

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Germany

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS054095

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS054095

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta

News

Executive Summary

Related Content

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert